A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c)
during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects
with Type 2 Diabetes Mellitus (T2DM)